A case series evaluating patient perceptions after switching from nusinersen to risdiplam for spinal muscular atrophy

Introduction/Aims In 2016, nusinersen became the first disease‐modifying medication approved by the U.S. Food and Drug Administration (FDA) for spinal muscular atrophy (SMA). With the later availability of risdiplam in 2020, individuals now have the option of switching from nusinersen to risdiplam. Limited published data exist to inform this decision. This study aims to evaluate the perceptions and experiences of adult participants and parents of minor participants who previously received nusinersen and switched to risdiplam for the treatment of SMA. Methods Institutional Review Board (IRB) approval was obtained from the Wake Forest IRB prior to the initiation of this study. A cross‐sectional, observational study, with qualitative and quantitative data gathered via questionnaire and medical record review, was performed. Inclusion criteria included (1) prior diagnosis of SMA, (2) previous treatment with nusinersen, and (3) change to treatment with risdiplam. No participants were excluded based on age. Results Fourteen participants—eight adults and six children—were enrolled in the study. Respondents noted improvements in physical function with each medication. Overall, respondents reported worse satisfaction with the method of delivery of the intrathecally delivered nusinersen compared to the orally‐delivered risdiplam, but no respondent reported negative overall satisfaction with either medication. A majority (78.6%) of respondents reported that switching from nusinersen to risdiplam was the correct decision. Discussion These results suggest that most patients are satisfied when switching from nusinersen to risdiplam, with the method of delivery being a primary factor.